American Association for Cancer Research
Browse

Supplementary Table S9 from Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration

Download (13.88 kB)
journal contribution
posted on 2023-04-04, 01:43 authored by Takao Morinaga, Takashi Inozume, Masahito Kawazu, Youki Ueda, Nicolas Sax, Kazuo Yamashita, Shusuke Kawashima, Joji Nagasaki, Toshihide Ueno, Jason Lin, Yuuki Ohara, Takeshi Kuwata, Hiroki Yukami, Akihito Kawazoe, Kohei Shitara, Akiko Honobe-Tabuchi, Takehiro Ohnuma, Tatsuyoshi Kawamura, Yoshiyasu Umeda, Yu Kawahara, Yasuhiro Nakamura, Yukiko Kiniwa, Ayako Morita, Eiki Ichihara, Katsuyuki Kiura, Tomohiro Enokida, Makoto Tahara, Yoshinori Hasegawa, Hiroyuki Mano, Yutaka Suzuki, Hiroyoshi Nishikawa, Yosuke Togashi

Sequencing summary.

Funding

MEXT | Japan Society for the Promotion of Science (JSPS)

Japan Agency for Medical Research and Development (AMED)

MEXT | JST | Fusion Oriented REsearch for disruptive Science and Technology (FOREST)

Chiba Prefecture Research Grant

Naito Foundation (内藤記念科学振興財団)

Takeda Science Foundation (公益財団法人　武田科学振興財団)

Mochida Memorial Foundation for Medical and Pharmaceutical Research (公益財団法人 持田記念医学薬学振興財団)

Japanese Foundation for Multidisciplinary Treatment of Cancer Foundation

Kanae Foundation for the Promotion of Medical Science (Kanae Foundation)

Yasuda Memorial Medical Foundation (Yasuda Medical Foundation)

MSD Life Science Foundation, Public Interest Incorporated Foundation (SD Life Science Foundation)

Kowa Life Science Foundation

Senri Life Science Foundation

Uehara Memorial Foundation (上原記念生命科学財団)

Japan Lung Cancer Society (JLCS)

Princess Takamatsu Cancer Research Fund

Kato Memorial Bioscience Foundation

Ono Medical Research Foundation

Inamori Foundation

Japan Respiratory Foundation

Ube Industries Foundation

History

ARTICLE ABSTRACT

Several patients experience mixed responses to immunotherapies, but the biological mechanisms and clinical significance remain unclear. Our results from clinical and mouse studies underscore that intertumoral heterogeneity alters characteristics of TILs even in the same patient, leading to mixed response to immunotherapy and significant difference in the outcome.

Usage metrics

    Cancer Research Communications

    Categories

    Keywords

    Tumor EvolutionSingle Cell TechnologiesImmunotherapyTumor MicroenvironmentImmune cells and the microenvironmentTumor HeterogeneityBiomarkersPrognostic biomarkers

    Licence

    CC BY

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC